Compare BridgeBio Pharma Inc (BBIO) vs Core and Main Inc (CNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Core and Main Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Core and Main Inc trades at $46.73 (market cap $8.67B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | CNM | |
|---|---|---|
Market Cap | $16.61B | $8.67B |
Sector | Health | Technology |
52-Week High | $90.17 | $66.98 |
52-Week Low | $47.29 | $42.37 |
Enterprise Value | $18.16B | $10.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Core & Main (CNM) trades at $46.55, up 2.33% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 23.73% ROE and 5.87% net margin, supported by resilient municipal demand. Recent news highlights institutional activity, including CalSTRS increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is mixed: analyst consensus leans bullish with 57% buy ratings, but technical indicators suggest near-term pressure. Key risks include high debt levels and residential market weakness. Upside hinges on margin expansion and FY26 revenue guidance of $7.8–7.9B (Business Wire, 2026-06-25).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
